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Abstract  
 
Background: It is unclear whether generalized anxiety disorder (GAD) has a specific relationship to 
pain syndromes, going beyond the established association of pain with anxiety syndromes in general.  
Methods: Mental disorders were assessed in a community sample (N = 4181; 18–65 years) using the 
DSM-IV/M-CIDI. Several threshold definitions were used to define GAD and medically unexplained 
pain.  
Results: The association between pain and GAD (odds ratio, OR = 5.8 pain symptoms; OR = 16.0 pain 
disorder) is stronger than the association between pain and other anxiety disorders (OR = 2.4 pain 
symptoms; OR = 4.0 pain disorder). This association extends to subthreshold level definitions of GAD 
with some indication for a non-linear dose–response relationship. The GAD-pain link cannot 
sufficiently be explained by demographic factors, comorbid mental or physical disorders.  
Conclusions: The association of pain and generalized anxiety is not artifactual. Compared to other 
anxiety syndromes, it appears to be stronger and more specific suggesting the need to explore clinical 
and public health implications. 
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1. Introduction  
 
Generalized anxiety disorder (GAD) is a common condition in the general population 
(lifetime prevalence 5–6%) associated with significant individual and societal burden as well 
as tremendous health care costs (Olfson & Gameroff, 2007; Ormel et al., 2008; Ruscio et al., 
2007; Wittchen, Beesdo, & Kessler, 2002). The occurrence of GAD with other mental 
disorders, particularly depression, has been studied extensively (Judd et al., 1998; Kessler, 
Walters, & Wittchen, 2004; Moffitt et al., 2007; Wittchen, Kessler, et al., 2002), but the 
relationship between GAD and pain conditions has only recently received some research 
attention. Primary care patients with GAD frequently present to their general practitioner with 
pain as initial reason for help-seeking (Wittchen, Kessler, et al., 2002). In addition, GAD 
patients suffer greater overall pain interference, compared to unaffected patients, and also 
have disproportionally high medical health care costs (Olfson & Gameroff, 2007).  
 
Recent epidemiologic data provide evidence for strong associations between GAD and pain 
conditions (Demyttenaere et al., 2007; Gureje et al., 2008; McWilliams, Cox, & Enns, 2003; 
McWilliams, Goodwin, & Cox, 2004; Von Korff, Crane, et al., 2005). For example, in the 
National Comorbidity Survey—Replication (NCS-R), GAD appeared among several anxiety 
disorders to be particularly strongly related to chronic back pain (Von Korff, Crane, et al., 
2005). A similar finding was reported from the World Mental Health surveys across 18 
developing and western countries (Demyttenaere et al., 2007) where GAD was found to have 
a higher pooled odds ratio than the other anxiety disorders, major depression and alcohol 
abuse/dependence. Furthermore, there was an association between number of painful body 
sites and GAD (Gureje et al., 2008). McWilliams et al. (2004) also found stronger 
associations for GAD compared to panic attacks and major depression in two out of three pain 
conditions (arthritis and migraine) in the Midlife Development in the United States Survey 
(MIDUS), even after adjustment for sociodemographic variables and other pain and medical 
conditions. Moreover, GAD in this study was the mental condition that had the strongest 
association with multiple pain conditions. In the German Health Survey (GHS), from among a 
wide range of specific depressive and anxiety disorders, GAD was most strongly associated 
with clinically significant pain symptoms (Beesdo et al., 2007). Interestingly, all GAD 
sufferers reported pain and the association seemed to be particularly pronounced with 
medically unexplained pain symptoms and pain disorder.  
 
In summary, recent findings indicate a strong relationship between GAD and pain syndromes. 
However, to date, there has been no comprehensive investigation examining the nature and 
the specificity of this finding. Yet, it is noteworthy that there are a number of observations 
and a priori assumptions that make the specificity of the association between GAD and pain 
highly probable.  
 
First, GAD differs from other anxiety disorders in several aspects. GAD has a different 
incidence pattern characterized by a later high risk period for first onset (mid-teens until later 
adulthood) (Beesdo, 2006; Bijl, de Graaf, Ravelli, Smit, & Vollebergh, 2002; Kessler et al., 
2005; Ruscio et al., 2005). GAD has been described as the most frequent anxiety disorder in 
the elderly (Beekman et al., 1998). This incidence pattern corresponds with that of chronic 
pain syndromes which are also notable for onsets until older age (Bellach, Ellert, & 
Radoschewski, 2000; Elliott, Smith, Penny, Smith, & Chambers, 1999; Eriksen, Jensen, 
Sjogren, Ekholm, & Rasmussen, 2003; McBeth & Jones, 2007; Torrance, Smith, Bennett, & 
Lee, 2006). Further, in contrast to some other anxiety disorders with a more variable symptom 
course, GAD-symptoms – by definition – have to occur almost daily over a time period of at 
least 6 months, and episodes persist with some waxing and waning of symptoms for many 
years (Wittchen & Hoyer, 2001). Similar patterns of course have been described for most 
chronic pain syndromes (Smith, Elliott, Hannaford, Chambers, & Smith, 2004). Therefore, 
one might expect a closer relationship between pain and GAD than other anxiety disorders.  
 
Second, despite no overlap between pain disorder and GAD in DSM-IV diagnostic criteria, 
both conditions share some features which would suggest a strong association between both 
conditions. Among such common features are core cognitive symptoms (such as anxious 
expectation), some physiological symptoms (such as muscle tension), hypervigilance 
symptoms (such as sleeping problems, irritability, and restlessness), and behavioral symptoms 
(such as avoidance). It should be noted that autonomic symptoms were deleted as mandatory 
diagnostic criteria for GAD in DSM-IV in favour of a list of symptoms that can broadly be 
characterized as a chronic hypervigilance syndrome. In this respect, GAD differs from the 
other anxiety disorders which again would suggest a particular relationship to pain.  
 
Third, there are some recent speculations on common psychological and (neuro-)biological 
mechanisms and pathways in fear/anxiety and pain conditions (Price, 2002), which indicate 
strong associations between them. Consistent with this, similar pharmacological (Grothe, 
Scheckner, & Albano, 2004; Gutierrez, Stimmel, & Aiso, 2003) as well as non-
pharmacological therapeutic interventions (Borkovec & Ruscio, 2001; Hoyer et al., 2009; 
Turner- Stokes et al., 2003) seem to work in both GAD and pain patients.  
 
Based on these considerations one would not only expect a significant relationship between 
pain syndromes and DSM-IV GAD, but also between pain syndromes and generalized anxiety 
syndromes below the full diagnostic threshold. To our knowledge, such relationships have not 
been studied. The aim of this current investigation is to use a large, nationally representative 
population sample to examine: (1) whether medically unexplained pain is more strongly 
associated with GAD than with other anxiety disorders, (2) whether medically unexplained 
pain is associated with generalized anxiety below the full diagnostic threshold, and (3) how 
pain and generalized anxiety occurring together are related to negative outcomes in terms of 
disability, quality of life, and service utilization. We focus on clinically significant, medically 
unexplained (somatoform) pain because of indications that particularly unexplained pain may 
be important in GAD (Beesdo et al., 2007). It should be noted, however, that there is an 
ongoing controversy surrounding this type of pain classification (Hiller, 2006; Kroenke, 2006; 
Mayou, Kirmayer, Simon, Kroenke, & Sharpe, 2005; Sharpe, Mayou, & Walker, 2006; 
Sullivan, 2000; Sykes, 2006). Some (Kroenke, 2006; Mayou et al., 2005; Sharpe et al., 2006) 
point out the theoretical and practical difficulties in categorizing symptoms to be „medically 
unexplained (somatoform)“ suggesting a simplified categorization and „etiologically neutral“ 
terminology for physical symptoms including pain. Others (Hiller, 2006), in contrast, 
emphasize the progress that has been made with research on somatoform diagnoses as mental 
disorders integrating biological, psychological, and social aspects.  
 
2. Method  
 
The data presented in this paper come from the German National Health Interview and 
examination survey, mental health supplement (GHS-MHS) conducted in 1998–1999. The 
survey was approved by the Institutional Review Board of the Robert Koch Institute (Berlin, 
Germany). All participants provided written informed consent. Aims, design, and methods of 
the survey have been described in detail elsewhere (Jacobi et al., 2002).  
 
2.1. Sample  
 
The GHS (core survey) covered a range of medical and social assessments in a multistage, 
stratified, cross-sectional, random sample of the general German population aged 18–79 
years, drawn from population registries (N = 7124; response rate: 61.5%). The MHS (one of 
several supplements) included a subsample of the core survey (N = 4181; conditional 
response rate: 87.6%). This subsample can be regarded as representative for the German 
noninstitutionalized adult population in the age-range of 18–65 years (Jacobi et al., 2002). 
Older individuals were excluded from the MHS due to unsatisfactory psychometric properties 
of the used diagnostic assessment instrument (the Munich Composite International Diagnostic 
Interview (DIA-X/M-CIDI)) in these populations (Knäuper & Wittchen, 1994).  
 
2.2. Measures  
 
2.2.1. Assessment of disorders  
 
Assessment of mental disorders was based on the Computer- Assisted Version (CAPI) of the 
Munich Composite International Diagnostic Interview (DIA-X/M-CIDI) (Wittchen & Pfister, 
1997; Wittchen, Lachner, Wunderlich, & Pfister, 1998), a modified version of the World 
Health Organization (WHO) CIDI, version 1.2, supplemented by questions to cover DSM-IV 
(APA, 1994) and ICD-10 criteria (WHO, 1993). The DIA-X/M-CIDI was administered by 
clinically trained interviewers (psychologists and MDs). Psychometric properties of the DIA-
X/M-CIDI were found to range between acceptable to very good (retest-reliability: kappa = 
0.45 for GAD to 1.00 for panic disorder; kappa = 0.62 for any somatoform disorder; validity: 
kappa = 0.50 for somatoform disorder to 0.96 for major depressive episode; kappa = 0.79 for 
any anxiety disorder (Lachner et al., 1998; Reed et al., 1998; Wittchen, 1994; Wittchen et al., 
1998). All analyses in this paper are based on 12- month prevalence criteria.  
 
2.2.1.1. Pain symptoms and pain disorder. Diagnosis of (somatoform) pain disorder was 
generated by using the standard DSM-IV/ M-CIDI algorithms (Wittchen & Pfister, 1997). In 
the somatoform disorders section of the DIA-X/M-CIDI, presence of the following painful 
conditions is initially assessed from the respondents on a lifetime basis: abdominal pain, back 
pain, joint pain, limb pain, chest pain, headache, excessively painful menstruation, rectal and 
genital pain, and other pain. For common experienced pain types (abdominal pain, back pain, 
headache, and painful menstruation) the threshold for positive endorsement was increased by 
asking whether the respondent has ever had „a lot of trouble“ with this pain. Whenever the 
respondent acknowledged having experienced at least one of these pain types, the interviewer 
enters a standardized complex set of probe questions to evaluate the nature of the complaint 
(Rubio-Stipec et al., 1993; Wittchen, Essau, Rief, & Fichter, 1993).  
 
There are several levels of probing before a pain symptom ultimately is considered to be 
„clinically significant“ and „medically unexplained.“ The probe questions start with 
establishing clinical severity/significance. A symptom is considered „clinically significant“ if: 
such symptom prompts seeking help from a medical doctor or other health professional; 
medication was used more than once for it; or the symptom interfered a lot with life or 
activities (criterion A). For headaches and painful menstruation, positive endorsement of 
medication use more than once was not considered as sufficient for establishing clinical 
significance. Here, respondents must have additionally reported medication prescription by a 
doctor (pertaining to headaches and painful menstruation), or the use of prescription-free 
medication at least three times a week (pertaining to headaches) (Wittchen & Pfister, 1997). 
Next, further complex probe questions were used to establish whether there are any physical 
or substance related factors that explain the occurrence of the pain symptom („medically 
explained“ pain). Only if the symptom was not (or not always) explained by a medical 
diagnosis (e.g., doctor’s diagnosis of migraine for headaches), an injury, or the use of 
medication, drugs or alcohol, it was rated as „medically unexplained.“ This was counted 
towards the DSM-IV criterion C (note that the controversial ‘psychological factors’ criterion 
(Hiller, 2006; Kroenke, 2006; Mayou et al., 2005; Sharpe et al., 2006; Sullivan, 2000; Sykes, 
2006) is particularly difficult to assess with a standardized instrument in an epidemiological 
study).  
 
If at least one painful condition was found to be present as clinically relevant and medically 
unexplained, further questions were asked regarding the recency of pain symptoms (12-month 
status) and regarding the diagnosis of pain disorder (criterion B). (1) Did the pain keep you 
from working or seeing friends or relatives for 6 months or more? (2) How much did the pain 
interfere with your life and daily activities? If the respondent acknowledged impairment for 6 
months or at least a lot interference with life, the diagnosis of pain disorder was made.  
 
DSM criterion D (the symptom is not intentionally produced or feigned) was not assessed by 
the DIA-X/M-CIDI. The exclusion criterion E (the pain is not better accounted for by a mood, 
anxiety, or psychotic disorder) is considered in the present analysis by providing the 
proportion of respondents who reported that their physician attributed their pain to „anxiety, 
panic attacks, or depression“.  
 
Keeping the controversy about somatoform pain and pain disorder in mind, we consider in the 
current paper and if not otherwise stated, three hierarchical, mutually exclusive pain groups as 
based on respondents’ self-reports: (1) no unexplained pain (no UP), representing individuals 
with either no clinically significant pain symptoms or with medically explained pain 
symptoms, (2) at least one medically unexplained pain symptom (UPS), and (3) pain disorder 
(PD) as per DIA-X/M-CIDI algorithms. Individuals with explained pain symptoms were 
combined with the no pain group for two reasons. First, recent findings of our group using the 
same sample showed that virtually all GAD patients reported some significant pain at some 
point during their life indicating an important role of unexplained pain in GAD (Beesdo et al., 
2007). Second, medically explained pain symptoms were assessed on a lifetime basis without 
assessing 12-month prevalence. Our group definition can be regarded as conservative because 
the inclusion of individuals with exclusively medically explained pain symptoms in the no UP 
group creates a stricter reference group than if these individuals were excluded from the 
analyses.  
 
2.2.1.2. GAD and generalized anxiety below the diagnostic threshold. The GAD section of the 
DIA-X/M-CIDI began with a screening question: „In the last 12 months, have you had a 
period of a month or more when most of the time you felt worried, tense, or anxious about 
everyday problems?“ The entire section was skipped if the respondent did not endorse this 
question. Respondents who reported at least 1 month of anxious worrying were asked to 
report the longest period (in the past 12 months) that they had felt worried. If this period was 
less than 3 months, the rest of the section was skipped. Those with at least 3 months of 
anxious worrying were asked the complete series of CIDI questions in this section to assess 
the DSM-IV GAD criteria (APA, 1994). Exclusionary criteria were not applied for the present 
diagnostic analyses to facilitate comparisons with the majority of other research on GAD that 
also does not apply these criteria. Previous work done by Carter, Wittchen, Pfister, and 
Kessler (2001) found that application of these criteria decreases the prevalence rate of GAD 
very little.  
 
Since most of the GAD section of the DIA-X/M-CIDI was skipped if the respondent reported 
less than 3 months of persistent anxious worrying, information about fulfilment of the other 
DSM-IV criteria for GAD was available only for those respondents with episode duration of 
at least 3 months. Three diagnostic threshold levels for GAD were defined for the purposes of 
examining the association with pain: (1) GAD symptoms—anxious worrying for at least 1 
month, (2) subthreshold GAD—anxious worrying for at least 3 months with at least two of 
the other DSM-IV criteria for GAD (B: uncontrollable worry, C: at least 3 out of 6 physical 
symptoms, or E: distress/impairment), and (3) threshold GAD—anxious worrying for at least 
6 months (DSM-IV criterion A) and all other DSM-IV criteria for GAD (B, C, and E). If not 
otherwise stated in the text, these groups are considered mutually exclusive. It is noteworthy 
that all DSM-IV criteria must be met during the last year for the application of a 12-month 
diagnosis of threshold GAD. This can be considered as very strict, especially regarding the A-
criterion which requires a 6-month period of persistent anxious worrying.  
 
2.2.1.3. Other mental disorders. Depressive disorders (major depression and dysthymia), 
anxiety disorders (specific phobia, social phobia, agoraphobia without panic disorder, phobia 
not otherwise specified (NOS), panic disorder with or without agoraphobia, and obsessive 
compulsive disorder (OCD)), and substance use disorders (alcohol abuse and dependence, 
nicotine dependence, illegal drug/medication abuse and dependence) were assessed using the 
DSM-IV/M-CIDI (Wittchen & Pfister, 1997) and considered for analyses as control variables 
if 12-month DSM-IV criteria were met.  
 
2.2.1.4. Physical disorders. A self-report questionnaire was used to assess presence of 44 
physical diagnoses from 16 disease groups (e.g., cardiac diseases, diabetes, cancer, allergies 
(Jacobi et al., 2002)). Considering this self-report, study doctors used a computer-assisted 
standardized interview to establish lifetime, 12-month and point prevalences of physical 
disorders. In this paper, we use a variable containing the number of physical disorders during 
the past 12 months (range 0–9) as control variable.  
 
2.2.2. Other measures  
 
2.2.2.1. Assessment of health related quality of life. The German version (Bullinger & 
Kirchberger, 1998; Ware & Sherbourne, 1992) of the well-validated self-report Medical 
Outcome Study 36-item short form (SF-36) (Bullinger et al., 1998; Butterworth & Crosier, 
2004; Ellert & Bellach, 1999; Hopman et al., 2000; McHorney, Ware, & Raczek, 1993; 
Sullivan & Karlsson, 1998) was used to assess eight health concepts (e.g., general health, 
physical function, emotional role) within the past 30 days. Principal components analysis has 
identified 2 dimensions of the SF-36: a physical component score and a mental component 
score (Ware et al., 1998). These scores were standardized to M = 50 and S.D. = 10.  
 
2.2.2.2. Assessment of disability. Similar to previous surveys (e.g., Sareen et al., 2006) past 4-
week disability was examined by the self-reported number of days individuals were unable to 
carry out usual daily activities (school, study, work, and household) due to: (1) mental 
(emotional, psychosomatic, or psychiatric) problems, (2) alcohol, drug or medication use, or 
(3) physical problems and illnesses. Number of overall disability days was generated by 
counting a full day for each day the respondent was totally unable to carry out usual activities 
and adding a half-day for each day the respondent was partly disabled to carry out usual 
activities. This summary variable reflects the number of disability days in the past month 
ranging from 0 to 28 days (if higher summary scores occurred they were coded to 28 days).  
 
2.2.2.3. Assessment of health care utilization. Assessment of health care utilization included 
self-reported data on the number of (1) general practice visits, (2) consultations with 
specialists (including neurologists, psychiatrists, and psychologists), and (3) days spent in 
hospital within the past 12 months. The total number of health care visits reflects the sum of 
the three domains.  
 
2.3. Statistical analyses  
 
Statistical analyses were carried out with the STATA software package, release 10.0 
(StataCorp, 2007). Data (percentages, %; means, M; standard deviations, S.D.; ratio’s from 
regressions, R) were weighted for age, gender, region and screening status in order to address 
different sampling probabilities and systematic nonresponse (Jacobi et al., 2002). The number 
of cases (N, n) is reported unweighted.  
 
In order to examine whether association between medically unexplained pain (UPS, PD) and 
GAD was greater than that of other anxiety disorders, three mutually exclusive diagnostic 
groups were created: no anxiety disorder, any anxiety disorder but no GAD, and DSM-IV 
GAD irrespective of comorbidity. Multinomial logistic regression models (odds ratios, OR 
with 95% confidence intervals, CIs) were used to quantify associations. Further, multinomial 
logistic regression models were also used to quantify associations between medically 
unexplained pain (UPS, PD) and the different levels of generalized anxiety (GAD symptoms, 
subthreshold GAD, and DSM-IV GAD). All associations were tested to see whether they 
persisted after adjustment for sociodemographic variables (age, gender) as well as comorbid 
mental and physical disorders. Statistical significance was evaluated at the 0.05 level using 
twotailed tests.  
 
Additionally, models were fit to examine correlates (e.g., quality of life, role impairment) for 
three mutually exclusive groups: generalized anxiety alone, medically unexplained pain alone, 
and comorbid generalized anxiety and medically unexplained pain. Here, generalized anxiety 
is composed of symptomatic, subthreshold and threshold GAD and medically unexplained 
pain is composed of UPS and PD. Associations with count variables (i.e., number of 
impairment days, number of health care visits) were assessed using mean ratios (MRs) from 
negative binomial regressions (Lawless, 1987). These regressions are useful for positively 
skewed distributions of infrequent events and the associated mean ratios reflect the change in 
the expected count of a particular event per unit increase in the covariate. Mean ratios from 
gamma regressions were used for gamma-distributed SF-36 outcomes. A significant ratio of 
<1 indicates a decrease of health related quality of life. We further assessed whether the 
combination of generalized anxiety and medically unexplained pain revealed superadditive 
associations (on the ln-outcome scale) fitting models with the main effect terms of generalized 
anxiety (yes/no) and pain (yes/no) and their interaction term. 
 
3. Results  
 
3.1. 12-Month prevalence of generalized anxiety and pain in the general population  
 
In the prior 12 months, 8.1% of the general population met criteria for PD; an additional 
15.4% experienced at least one UPS. The 12-month prevalence rates for threshold GAD, 
subthreshold GAD, and symptomatic GAD were 1.5%, 2.1%, and 4.2%, respectively. Women 
were significantly more frequently affected by generalized anxiety and pain at all diagnostic 
levels (OR range: 1.7–2.7, all p-values < 0.01). Higher rates with older age (age as 
dimensional variable) were found for DSM-IV threshold GAD only (OR = 1.03; 95% CI: 
1.01–1.05, p = 0.011).  
 
3.2. Is there a specific association between pain and DSM-IV GAD?  
 
Relative to individuals with no anxiety disorder, the proportion of both UPS and PD was 
increased among individuals with anxiety disorders, and particularly among those with GAD 
(Table 1, column percentages). And vice versa, among individuals with UPS and PD, 
increased proportions of any anxiety disorder and GAD were found as compared to 
individuals without unexplained pain (row percentages).  
 
As shown in Table 2, medically unexplained pain was associated with anxiety disorders other 
than GAD (column 1: OR = 2.4, 95% CI: 1.9–3.0, p < 0.001 for UPS; OR = 4.0, 95% CI: 3.0–
5.3, p < 0.001 for PD) but particularly with GAD (column 2: OR = 5.8, 95% CI: 3.0– 11.1, p 
< 0.001 for UPS; OR = 16.0, 95% CI: 8.6–29.8, p < 0.001 for PD). The pain-GAD association 
appeared to be strong and specific over and above the association of pain with other anxiety 
disorders (column 3: OR = 2.4, 95% CI: 1.2–4.7, p = 0.010 for UPS; OR = 4.0, 95% CI: 2.1–
7.6, p < 0.001 for PD). All associations persisted (all p-value < 0.05) even following 
adjustment for age, sex, comorbid depressive disorders, comorbid substance use disorders, 
and number of comorbid physical illnesses.  
 
3.3. Pain and generalized anxiety on different diagnostic levels  
 
Proportions for UPS or PD were not only increased among individuals with DSM-IV GAD, 
but also among individuals with generalized anxiety below the diagnostic threshold as 
compared to individuals without any GAD symptoms (Table 3, column percentages). Vice 
versa, all diagnostic levels of GAD occurred more frequently among individuals with UPS 
and particularly with PD as compared to individuals with no medically unexplained pain 
(Table 3, row percentages).  
 
Although more than 80% of individuals with UPS or PD reported no GAD symptoms, strong 
associations were found between pain and generalized anxiety on all diagnostic levels (crude 
OR range: 2.4–13.4, all p-values < 0.001; Table 4) with the exception of UPS and 
symptomatic GAD. There is some evidence for a non-linear dose–response relationship as 
indicated by increasing ORs towards stricter definitions of both disorders with a particularly 
pronounced association for PD and DSM-IV GAD (OR = 13.4, 95% CI: 7.2–24.8, p < 0.001).  
 
While adjusting for demographic variables decreased the associations only slightly, there was 
a major drop in the magnitude of the ORs when depressive disorders were added to the 
multiple model. However, only the association between PD and subthreshold GAD was 
attenuated. The model additionally adjusting for other anxiety disorders revealed a further 
modest decrease in OR size with OR attenuation for PD and symptomatic GAD. No further 
change in associations was found when substance use disorders and number of physical 
illnesses were added to the model. Therefore, the associations to DSM-IV GAD endured 
independent of effects of demographic variables and a number of comorbid conditions for 
UPS (OR = 3.6, 95% CI: 1.9–7.1, p < 0.001) and particularly PD (OR = 4.7, 95% CI: 2.3–9.5, 
p < 0.001), as was the association between UPS and subthreshold GAD (OR = 1.8, 95% CI: 
1.1–1.3, p = 0.020).  
 
To further rule out artifactual comorbidity between unexplained pain and generalized anxiety, 
we first examined the temporal order of onset of these conditions. One would expect 
misclassifications to be reflected in frequent onsets within the same year. However, only few 
cases with comorbid UPS/PD and subthreshold/threshold GAD (n = 101; note: no age of 
onset available for most respondents with symptomatic GAD) reported a same year onset (n = 
10, 9.4%). Pain began at least 1 year prior to GAD in the majority of cases (n = 71, 72.3%); a 
secondary onset of pain was found in one-fifth of the subjects (n = 20, 18.4).We also 
examined among respondents who were classified with unexplained pain and who consulted 
their medical doctor for at least one of their pain symptoms (n = 842 of the UPS/PD cases 
without comorbid generalized anxiety, n = 151 of the UPS/PD cases with comorbid 
symptomatic, subthreshold or threshold GAD) how frequently physicians – as per 
respondents’ report – directly attributed the pain to anxiety, panic attacks, or depression. Also 
providing evidence against misclassification, very few of the respondents with UPS/PD (n = 
2/842, 0.2% of the respondents without comorbid generalized anxiety, n = 4/151, 2.6% of the 
respondents with comorbid generalized anxiety) stated that their physician explained their 
pain by anxiety, panic or depression. In contrast, 16.8% (n = 145) of the respondents with 
UPS/PD alone and 27.7% (n = 42) of the respondents with comorbid UPS/PD and generalized 
anxiety reported that their pain was specifically attributed to nerves or stress by their 
physician.  
 
3.4. Correlates of generalized anxiety and pain  
 
Table 5 shows measures of quality of life, disability, and health care utilization for four 
mutually exclusive groups: individuals with: (1) no unexplained pain symptoms and no 
generalized anxiety, (2) unexplained pain (UPS or PD) alone, (3) generalized anxiety 
(symptomatic GAD, subthreshold GAD, or threshold GAD) alone, and (4) both unexplained 
pain and generalized anxiety.  
 
Compared to individuals without unexplained pain and generalized anxiety, all three 
syndrome groups – unexplained pain alone, generalized anxiety alone, and co-occurring 
unexplained pain and generalized anxiety – were associated with decreased quality of life, 
disability and health care utilization (all p-values < 0.05) with the exception that individuals 
with generalized anxiety alone, as expected, did not report reduced physical health related 
quality of life or disability due to physical problems. However, these individuals had a 
significantly more decreased mental health related quality of life (OR = 0.90, 95% CI: 0.86–
0.93, p < 0.001) and increased disability days due to mental health problems (OR = 2.6, 95% 
CI: 1.5–4.5, p = 0.001) as compared to individuals with unexplained pain alone. As expected, 
the group with both unexplained pain and generalized anxiety reported the lowest quality of 
life and greatest disability and health care utilization.  
 
In comparison to individuals with unexplained pain alone, the co-occurrence of generalized 
anxiety in unexplained pain was associated with decreased mental health related quality of life 
(OR = 0.78, 95% CI: 0.74–0.82, p < 0.001), a greater number of disability days due to mental 
problems (OR = 5.4, 95% CI: 3.3–8.8, p < 0.001), and a higher number of health care visits 
(OR = 1.5, 95% CI: 1.2–1.9, p = 0.001). Compared to the generalized anxiety alone group, 
individuals with co-occurring unexplained pain and generalized anxiety reported significantly 
lower mental (OR = 0.87, 95% CI: 0.82–0.93, p < 0.001) and physical (OR = 0.93, 95% CI: 
0.89–0.97, p = 0.001) health related quality of life, as well as more disability days due to 
mental problems (OR = 2.1, 95% CI: 1.2–3.7, p = 0.009), and a greater number of health care 
visits (OR = 1.4, 95% CI: 1.1–1.9, p = 0.012). In the model with generalized anxiety (yes/ 
no), pain (yes/no) and the interaction anxiety x pain we only found one significant interaction: 
the main effects of pain (ratio main effect estimated as 0.95 in this model) and generalized 
anxiety (ratio main effect estimated as 0.85 in this model) on mental health related quality of 
life (SF36) were significantly enhanced when both conditions were present (interaction: R = 
0.92, 95% CI: 0.86– 0.98, p = 0.009).  
 
Adjusting all analyses for comorbid anxiety and depressive disorders, as the both groups of 
diagnoses having the most influence on the pain-generalized anxiety association, we found 
that most associations with negative correlates remained significant (Table available upon 
request).  
 
4. Discussion  
 
Using 12-month data from a large general population sample we examined the association 
between medically unexplained pain and GAD as assessed by a standardized diagnostic 
interview. The major findings emerging from our analyses are: (1) GAD was specifically and 
more strongly than other anxiety disorders associated with medically unexplained pain, (2) 
this specific association also applied to subthreshold levels of GAD with some indication of a 
non-linear dose–response relationship, (3) associations were not attributable to demographic 
factors or comorbid mental and physical disorders, and (4) the co-occurrence of medically 
unexplained pain and generalized anxiety was associated with poorer negative outcomes in 
terms of quality of life, disability, and health care utilization.  
 
The conceptualization and classification of both GAD (Beesdo, 2006; Hettema, 2008; Hoyer, 
Beesdo, Becker, & Wittchen, 2003; Kessler, 2002; Mennin, Heimberg, Fresco, & Ritter, 
2008; Moffitt et al., 2007; Watson, O’Hara, & Scott, 2008) and unexplained, somatoform 
conditions (Hiller, 2006; Kroenke, 2006; Mayou et al., 2005; Sharpe et al., 2006; Sullivan, 
2000; Sykes, 2006) has been surrounded by controversy. Acknowledging this controversy, the 
current study provides epidemiological evidence that the association between generalized 
anxiety and medically unexplained pain is strong, not due to diagnostic artifact, and has 
clinical and public health implications.  
 
Some limitations of our study must be carefully considered for interpretation of our findings. 
We assessed and categorized clinically significant, medically unexplained pain symptoms and 
pain disorder based on participants’ response to DIA-X/M-CIDI questions. In our population-
based sample, we were unable to confirm clinical significance or the unexplained nature of 
pain symptoms through medical records or routine diagnostic work-up. Thus, our diagnostic 
categories rely on respondents’ self-report. The DIA-X/M-CIDI diagnoses of pain disorder 
therefore have imperfect validity. However, diagnostic categorizations were based on a series 
of sophisticated DIA-X/M-CIDI probe questions. For example, several probe questions 
explicitly asked for doctor’s diagnoses or test results in relation to the pain. Only if physical 
and substance related factors were ruled out was the pain then classified as „medically 
unexplained“. Moreover, in order to rule out misclassification and thus artifactual comorbidity 
between unexplained pain and generalized anxiety, we investigated whether physicians 
attributed the pain explicitly to anxiety (or depression), or whether pain and generalized 
anxiety symptoms emerged at the same time. None of these explanations sufficiently 
accounted for our findings. It is also important to note that artifactual comorbidity is not 
created by the DSM-IV given the fact that GAD and pain disorder do not share any symptom 
criteria. Thus, there is evidence for these two distinct entities that appear to be strongly 
associated.  
 
Consistent with the few available recent epidemiological findings (Demyttenaere et al., 2007; 
Gureje et al., 2008; McWilliams et al., 2004; Von Korff, Crane, et al., 2005), we also found 
associations between pain and other anxiety disorders (GAD excluded from the combined 
group). The association between GAD and pain, however, was particularly pronounced. As 
some anxiety disorders known to have strong associations to pain (such as posttraumatic- 
stress disorder) were not assessed in our study, it remains to be delineated to what degree the 
specificity in the association between GAD and pain over and above the other anxiety 
disorders would persist if these conditions were included in the combined anxiety group. 
Unfortunately, lack of power prevented us to examine the specificity of the GAD-pain 
association in regard to each of the individual anxiety disorders. However, we controlled the 
GAD-pain association for comorbid mental disorders as well as physical disorders and 
demographic factors and the association remained, supporting the robustness of our finding. 
Among control variables, depressive disorders had the largest, though not attenuating effect 
on the GAD-pain association. Given the well-known high rates of comorbidity between GAD 
and depression (Kessler et al., 2004), our findings suggest that the GADpain association is 
independent and not confounded by comorbid depression. This also is indirect support for the 
view that GAD is a discrete disorder and not only a manifestation of other psychopathology 
such as depressive disorders (Kessler, 2002).  
 
A closer investigation of symptomatic and subthreshold definitions of GAD also revealed 
associations with medically unexplained pain, albeit these were lower, less consistent and less 
stable when confounding factors were controlled. These findings, however, suggest that 
generalized anxiety and medically unexplained pain, in addition to being associated on a 
DSM-IV disorder level, are also related on a continuum of symptom levels. There is 
indication of a non-linear dose–response relationship as the association was observed to 
increase from the symptom to the disorder levels of the conditions with an especially 
pronounced association between DSM-IV defined GAD and pain disorder.  
 
Reasons for the strong association between GAD and pain are currently unclear. Several 
theoretical explanations are possible. Three of them are the most viable for future 
investigation of the mechanisms and pathways of this association. First, there may be a direct 
link between GAD and pain. Experience of pain symptoms may trigger anxious worrying and 
therefore may contribute to the development of GAD, and vice versa, the muscular tension 
associated with GAD may lead to pain symptoms. Given our finding of a non-linear dose–
response relationship between generalized anxiety and pain, it may be assumed that these 
processes are more likely to occur if worrying and pain reach a certain level of severity or 
chronicity to trigger the onset of the other condition. Our exploration of temporal order of 
onset would support the bi-directional causal hypothesis with some indication that pain is 
more likely to trigger GAD than the reverse. This, however, needs further investigation, 
optimally in prospective longitudinal observational studies.  
 
The potential second explanation for comorbidity between pain and GAD is the perpetuating 
or exacerbating role of anxious worrying and pain after the initial onset of the other condition. 
That is, unexplained pain may be a source for more anxious expectation and worrying among 
individuals with generalized anxiety and therefore a mediator for the development of 
threshold GAD. Vice versa, anxious worrying occurring among individuals with pain 
symptoms may exaggerate awareness and attention to pain and therefore contribute to pain 
persistence and chronicity.  
 
Third, other variables such as biological, psychological and/or social factors may contribute to 
both GAD and pain by acting either as mediators or vulnerability factors in a common 
pathogenetic pathway. For example, cognitive distortions (e.g., catastrophizing, fear of pain, 
and pain/anxiety sensitivity) (Asmundson, Norton, & Vlaeyen, 2004; Cohen & Rodriguez, 
1995; Norton & Asmundson, 2004; Rief & Broadbent, 2007), dysfunctional behaviors (e.g., 
avoidance, reassurance seeking) (Asmundson et al., 2004; Cohen & Rodriguez, 1995; Norton 
& Asmundson, 2004; Rief & Broadbent, 2007) or neuro-chemical processes (e.g., dysfunction 
in serotonergic and noradrenergic neurotransmitter systems) (Cohen & Rodriguez, 1995; Rief 
& Broadbent, 2007; Smith, Macfarlane, & Torrance, 2007) arising from experiencing pain or 
GAD may be associated with the onset of the other condition (mediator-hypothesis) or may be 
the vulnerability for the independent development of both conditions (common pathogenetic 
vulnerability hypothesis). Further research is necessary to investigate the role of these 
possible explanations for the GAD-pain association and, in particular, to identify the 
mechanisms contributing to the specificity of this association for GAD in contrast to other 
anxiety disorders.  
 
Identification of the contributors and causes of the high comorbidity between pain and GAD 
is important, particularly in light of our finding that the GAD-pain co-occurrence is linked to 
more adverse negative correlates such as higher disability, decreased quality of life, and 
increased service utilization relative to individuals with only one of these two conditions. 
Clinicians should be aware of the strong relationship between pain and GAD, and assess 
anxious worrying and more severe GAD-levels in patients presenting with (unexplained) pain 
and vice versa. Diagnosis of GAD frequently presents a greater challenge than asking and 
following up on pain symptoms. As shown in a primary care study, GAD is frequently not 
recognized, correctly diagnosed and treated by physicians (Wittchen, Kessler, et al., 2002). 
This may be the case because patients with GAD present with pain as their primary presenting 
complaint rather than with anxiety or worry. Yet, there are feasible screening instruments 
(GAD-Q-IV, Newman et al., 2002; ASQ-15, Wittchen & Boyer, 1998) available to assist 
clinicians’ evaluations.  
 
If both conditions are present, the clinical implication for improved treatment is to consider 
intervention methods known to be effective in both GAD and pain. Such treatment options 
include both pharmacologic (Allgulander et al., 2007; Briley, 2004; Crofford et al., 2005; 
Grothe et al., 2004; Meoni, Hackett, & Lader, 2004; Mitte, 2005; Montgomery, Tobias, 
Zornberg, Kasper, & Pande, 2006) and psychological interventions (Borkovec & Ruscio, 
2001; Hoyer et al., 2009; Turner-Stokes et al., 2003). An optimized treatment would improve 
patient care. For example, prescribing a medication known to be effective for both conditions 
reduces the number of medications, drug–drug interactions, and side effects. For non-
pharmacologic treatment, cognitive-behavioral psychotherapeutic (CBT) approaches are the 
most promising (Borkovec & Ruscio, 2001; Hoyer et al., 2009; Turner-Stokes et al., 2003). 
Several CBT interventions target similar mechanisms of change related to both conditions. 
For example, a common element in pain and GAD treatment is relaxation training to decrease 
muscle tenderness and symptoms of hypervigilance. The fear of pain and also the fear of 
experiencing anxiety may be challenged with cognitive restructuring or exposure therapy. 
Confrontation interventions also target decreasing avoidance and increasing physical activity 
and goal-directed behaviour.  
 
Given high prevalence of GAD and pain-conditions in the community, it appears also 
important to test the efficacy of prevention and early intervention programs in order to reduce 
the risk for the development of the full-blown condition and secondary complications. 
Goodwin and Gorman (2002) showed in a US-population sample (NCS) that treatment of 
GAD with psychotropic medications significantly decreased the risk for subsequent onset of 
major depression. It remains to be investigated whether GAD treatment also reduces the onset 
of pain conditions and whether early intervention among individuals with pain decreases the 
risk for the development of GAD. Two recent primary care studies assessing the efficacy of 
brief CBT programs for enhancing chronic back pain are promising in regard to the latter 
question, as they showed reductions in back-related worries and fear-avoidance beliefs 
(Moore, VonKorff, Cherkin, Saunders, & Lorig, 2000; Von Korff, Balderson, et al., 2005).  
 
In conclusion, this study based on a large epidemiological sample provides evidence for: (a) a 
strong association between medically unexplained pain and GAD on a disorder and 
syndromal level, (b) diagnostic specificity for the pain association with GAD versus other 
anxiety syndromes, and (c) high magnitude of this association persisting even when adjusting 
for comorbid conditions. Co-occurrence of unexplained pain with both subthreshold and 
threshold levels of GAD represents a substantial health problem given their high prevalence, 
impairment/disability, and health care utilization rates. Greater recognition of these comorbid 
conditions and understanding the pathways and mechanisms of co-occurrence may lead to 
better treatment strategies as well as prevention of secondary long-term complications.  
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